ArticleEmerging infectious diseases2015
Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.Malaria journal · 2021Pooled it
- The usual suspect-malaria? Diagnostic challenges in post-artesunate delayed haemolysis: a clinical laboratory perspective through a case report.Malaria journal · 2025Review
- Post-Artesunate Delayed Hemolysis: Anything That Can Go Wrong Will Go Wrong-Murphy's Law.Clinical case reports · 2025Article
- Post-Artesunate Delayed Hemolysis in Pediatric Malaria Patients in the United States.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Acute Kidney Injury and Post-Artesunate Delayed Haemolysis in the Course ofPathogens (Basel, Switzerland) · 2024Article
- Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals.BMC infectious diseases · 2023Observational
- Post-treatment haemolysis is common following oral artemisinin combination therapy of uncomplicated malaria in travellers.Journal of travel medicine · 2023Observational
- Blackwater Fever Treated with Steroids in Nonimmune Patient, Italy.Emerging infectious diseases · 2023Article
- Post-Artesunate Delayed Hemolysis: A Review of Current Evidence.Tropical medicine and infectious disease · 2023Review
- Article
- Pitting of malaria parasites in microfluidic devices mimicking spleen interendothelial slits.Scientific reports · 2021Article
- Predictors of outcome in childhoodVirulence · 2020Review
- Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India.Malaria journal · 2020Observational
- Determinants of post-malarial anemia in African children treated with parenteral artesunate.Scientific reports · 2019Article
- Donor-derived CD4Bone marrow transplantation · 2019Article
- Anaemia and malaria.Malaria journal · 2018Review
- Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa.BMC infectious diseases · 2017Article
- Malaria parasite clearance.Malaria journal · 2017Review
- Severe malaria in Europe: an 8-year multi-centre observational study.Malaria journal · 2017Observational
- Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria.Emerging infectious diseases · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anemia has been observed in ≈20% of travelers who receive artesunate, ≈60% of whom require transfusion. This finding could discourage physicians from using artesunate. We prospectively evaluated a cohort of 123 patients in France who had severe imported malaria that was treated with artesunate; our evaluation focused on outcome, adverse events, and postartesunate delayed-onset hemolysis (PADH). Of the 123 patients, 6 (5%) died. Overall, 97 adverse events occurred. Among the 78 patients who received follow-up for >8 days after treatment initiation, 76 (97%) had anemia, and 21 (27%) of the 78 cases were recorded as PADH. The median drop in hemoglobin levels was 1.3 g/dL; 15% of patients with PADH had hemoglobin levels of <7 g/dL, and 1 required transfusion. Despite the high incidence of PADH, the resulting anemia remained mild in 85% of cases. This reassuring result confirms the safety and therapeutic benefit of artesunate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.